Analysts Set Artivion, Inc. (NYSE:AORT) PT at $44.17

Shares of Artivion, Inc. (NYSE:AORT) have been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $44.1667.

AORT has been the topic of a number of recent analyst reports. Stifel Nicolaus set a $45.00 price target on shares of Artivion in a research report on Monday, June 1st. Wall Street Zen lowered shares of Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Canaccord Genuity Group restated a “buy” rating and set a $36.00 price objective on shares of Artivion in a report on Tuesday, June 16th. Citizens Jmp lowered their price objective on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a research report on Friday, May 8th. Finally, LADENBURG THALM/SH SH upgraded shares of Artivion from a “neutral” rating to a “buy” rating and set a $42.00 target price on the stock in a research note on Friday, April 10th.

Artivion Price Performance

AORT opened at $24.14 on Monday. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.86 and a quick ratio of 2.80. The company has a market capitalization of $1.17 billion, a price-to-earnings ratio of 100.58 and a beta of 1.26. The firm’s fifty day moving average price is $23.36 and its two-hundred day moving average price is $33.72. Artivion has a 1 year low of $19.16 and a 1 year high of $48.25.

Insider Activity at Artivion

In related news, SVP Andrew M. Green sold 44,001 shares of Artivion stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total value of $910,820.70. Following the sale, the senior vice president owned 60,259 shares of the company’s stock, valued at approximately $1,247,361.30. The trade was a 42.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.30% of the company’s stock.

Institutional Trading of Artivion

A number of large investors have recently bought and sold shares of AORT. Caitong International Asset Management Co. Ltd purchased a new position in shares of Artivion during the 3rd quarter valued at $27,000. Rockefeller Capital Management L.P. increased its holdings in Artivion by 150.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after acquiring an additional 399 shares during the last quarter. Larson Financial Group LLC increased its holdings in Artivion by 148.5% in the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after acquiring an additional 563 shares during the last quarter. USA Financial Formulas raised its stake in Artivion by 163.5% in the 4th quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock valued at $52,000 after acquiring an additional 703 shares during the period. Finally, Smartleaf Asset Management LLC raised its stake in Artivion by 47.7% in the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after acquiring an additional 538 shares during the period. 86.37% of the stock is owned by hedge funds and other institutional investors.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.